Insulet Corporation will present new clinical evidence related to the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) at the 17thInternational Conference on Advanced Technologies & Treatments for Diabetes (ATTD) taking place March 6 - 9, 2024 in Florence, Italy, and online. With data on more than 100,000 users in the U.S. now available, Dr. Gibb and others will share new insights, including outcomes for those using the system for more than one year, data on users with low insulin requirements, and how the system responds to a missed meal bolus in the real world. An earlier analysis of the Real-World Evidence database as of July 2023 was recently published in Diabetes Technology and Therapeutics.

The paper presents the larger published U.S. dataset in the current AID landscape and demonstrates positive clinical outcomes under real-world conditions across a diverse population, including prior pump and MDI users, those on Medicare and Medicaid, and across all age groups greater than two years. Users at an average target of 110 mg/dL achieved nearly 70% Time in Range while maintaining very low rates of hypoglycemia. Chaired by Dr. Ly, the symposium will focus on Omnipod 5 and the importance of AID technology as standard of care for people with diabetes.

Clinical evidence from Insulet's Omnipod 5 Real-World Evidence database and results from the Company's EVOLUTION Study (the first feasibility study of Insulet's work to advance their AID algorithm) will be presented. Dr. Ly will also provide a Company update on future product innovations. speakers will include: Dr. Paolo di Bartolo, Chief of Ravenna Diabetes Center at the Romagna Local Health Authority in Italy.

Prof. May Ng, OBE Honorary Professor, Consultant Pediatric Endocrinologist at Mersey West Lancashire teaching Hospitals, Edge Hill University and University of Liverpool in the United Kingdom. Dr. Martin de Bock, Associate Professor and Pediatric Endocrinologist at the University of Otago, Christchurch in New Zealand.